Role of immunocompetent cells in nonimmune renal diseases

Kidney International

Volumn 59, Issue 5, 2001, Pages 1626-1640

  Rodríguez Iturbe, Bernardo ^a,b,c   Pons, Héctor ^a,b,c   Herrera Acosta, Jaime ^a,b,c   Acosta, Herrera ^a,b,c   Johnson, Richard J ^a,b,c,d  

^a HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cell activation; Hypertension; Lymphocytes; Macrophages; Progressive renal disease; Proteinuria; Tubulointerstitial injury

Indexed keywords

DIABETES MELLITUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOCOMPETENCE; KIDNEY DISEASE; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; NEPHROTOXICITY; OBSTRUCTIVE UROPATHY; PRIORITY JOURNAL; REVIEW;

EID: 0035045596     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0590051626.x     Document Type: Article

References (219)

1. In vitro evidence for cellular hypersensibility to glomerular basement-membrane antigens in human glomerulonephritis
2. What are sensitized cells doing in glomerulonephritis?
3. The role of lymphocytes in the progression of interstitial disease
4. Progression of renal damage in human glomerulonephritides: Is there a sleight of hand in winning the game?
5. Prevention of progression of renal fibrosis: How far are we?
6. Relationship between renal function and histologic changes found in renal biopsy specimens from patients with persistent glomerulonephritis
7. Structural-functional correlations in renal disease. II. The correlations
8. On the progression of chronic renal disease
9. Pathogenesis of chronic renal failure in the primary glomerulopathies, renal vasculopathies and chronic interstitial nephritides
10. Tubulointerstitial changes as a major determinant in the progression of renal damage
11. T cells and macrophages and their role in renal injury
12. The pathogenic role of macrophage migration inhibitory factor in immunologically induced kidney disease in the rat
13. Up-regulation of macrophage colony-stimulating factor (M-CSF) and migration inhibitory factor (MIF) expression and monocyte recruitment during lipid-induced glomerular injury in the exogenous hypercholesterolaemic (ExHC) rat
14. Pathogenesis and therapy of interstitial nephritis
15. Tubulointerstitial injury following glomerulonephritis
16. Ischemic acute tubular necrosis induces and extensive local cytokine response
17. Experimental chronic renal ischemia: Morphologic and immunologic studies
18. Characterization of inflammatory cells in autoimmune tubulointerstitial nephritis in rats
19. Interstitial nephritis induced by protein overload proteinuria
20. Acute tubulointerstitial nephritis associated by aminonucleoside nephrosis
21. Characterization of the interstitial cellular infiltrate in experimental chronic cyclosporine nephropathy
22. Mechanism of proteinuria: Effect of parenteral bovine albumin injections on hemoglobin excretion in rats
23. Proteinuria related to hyperproteinemia in dogs following plasma given parenterally: A renal threshold for plasma proteins
24. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein overload proteinuria
25. Tubular catabolism of albumin is associated with the release of an inflammatory lipid
26. Fine structural alterations in the rat following intraperitoneal bovine albumin
27. A scanning and transmission electron microscopic comparison of puromycin aminonucleoside-induced nephrosis to hyperalbuminemia-induced proteinuria with emphasis on kidney podocyte pedicel loss
28. In vitro alternative pathway activation of complement by the brush border of proximal tubules of normal rat kidney
29. Renal changes in experimental hypercholesterolemia in normal and subdiabetic rabbits. II. Long-term studies
30. Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease
31. Induction of glomerulosclerosis by dietary lipids: A functional and morphologic study in the rat
32. Renal injury of diet-induced hypercholestemia in rats
33. Cholestyramine resin ameliorates chronic aminonucleoside nephrosis
34. A putative role of hypercholesterolemia in progressive glomerular injury
35. Hyperlipemia and progressive renal disease
36. Effect of lipid abnormalities on the progression of renal damage: Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis
37. Monocytes and focal glomerulosclerosis
38. Intraglomerular foam cells and human focal glomerulosclerosis
39. Lipids and the kidney
40. Interstitial inflammation and fibrosis in rats with diet induced hypercholesterolemia
41. Pyelonephritis: Pathologic features
42. Atherosclerosis: An inflammatory disease
43. Hyperfiltration of remnant nephrons: A potentially adverse response to renal ablation
44. A progressive glomerulosclerosis occurring in partial five-sixth nephrectomy
45. Haemodynamically mediated glomerular injury: The end of a 15-year-old controversy?
46. Glomerular cell proliferation and PDGF expression precede glomerulosclerosis in the remnant kidney model
47. Angiotensin II induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta
48. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells
49. Transforming growth factor β1 and the renal injury following subtotal nephrectomy in the rat: Role of the renin-angiotensin system
50. Chronic effects of dietary protein in the rat with intact and reduced renal mass
51. Effect of dietary protein on renin and angiotensinogen gene expression after renal ablation
52. Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney
53. Mycophenolate mofetil attenuates renal injury in the rat remnant kidney
54. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats
55. Focal glomerulosclerosis in the remnant kidney model - An inflammatory disease mediated by cytokines
56. Macrophage and myofibroblast proliferation in remnant kidney. Role of angiotensin II
57. Combining an antiproteinuric approach with mycophenolate mofetil suppresses progressive nephropathy of experimental animals
58. Unilateral obstructive uropathy in the rabbit. I. Early morphologic, physiologic and histochemical changes
59. Proliferation of renal interstitial cells following injury induced by ureteral obstruction
60. Metabolic and cellular alterations underlying the exaggerated renal prostaglandin and thromboxane synthesis in ureter obstruction in rabbits
61. Macrophage-dependent arachidonate metabolism in hydronephrosis
62. Pathophysiology of obstructive nephropathy
63. Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney
64. Thromboxane A2 and prostacyclin production by lipopolysaccharide-stimulated peritoneal macrophages
65. Increased expression of TGF-β1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation
66. Congenital polycystic kidney disease
67. A hereditary model of slowly progressive polycystic kidney disease in the mouse
68. Growth factor gene expression in kidney of murine polycystic kidney disease
69. Upregulation of platelet-derived growth factor A and B gene expression in alveolar macrophages in individuals with idiopathic pulmonary fibrosis
70. Activated peripheral blood mononuclear cells in IgA nephropathy express platelet-derived growth factor
71. Regulation of insulin-like growth factor I gene expression in the human macrophage-like cell line U937
72. Molecular insights into renal interstitial fibrosis
73. Molecular mechanisms of diabetic renal hypertrophy
74. Intercapillary lesions in glomeruli of the kidney
75. The renal tubulointerstitium in diabetes mellitus
76. Structural-functional relationships in diabetic nephropathy
77. Renal interstitial expansion in insulin-dependent diabetes mellitus
78. Leukocyte analysis using monoclonal antibodies in human glomerulonephritis
79. Role of Amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy
80. Overview: Renal physiology and pathophysiology of aging
81. The aging kidney: Insights from experimental studies
82. Aging and the kidney
83. Mesangial lesion and focal glomerulosclerosis in the aging rat
84. Age-related nephropathy in laboratory rats
85. Aging-associated change in extracellular matrix
86. Tubulointerstitial disease in aging: Evidence for underlying peritubular capillary damage, a potential role for renal ischemia
87. Age-related increase in expression of TGF-β1 in the rat kidney: Relation to morphologic changes
88. Evolution of tubulointerstitial fibrosis in experimental renal infection and scarring
89. Experimental pyelonephritis: The effect of chronic active pyelonephrhitis on renal function
90. Transforming growth factor-β1 in hypertensive renal injury in Dahl salt-sensitive rats
91. Tubulointerstitial injury and loss of nitric oxide synthases parallel the development of hypertension in the Dahl-S rat
92. Heterogeneity in the appearance and distribution of macrophage subsets and their possible involvement in hypertensive vascular lesions in rats
93. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR
94. Renal injury and salt-sensitive hypertension after exposure to catecholamines
95. Salt-sensitive hypertension develops after short-term exposure to angiotensin II
96. Early interstitial changes in hypertension-induced renal injury
97. Renal proliferation and phenotypic changes in rats with two-kidneys one-clip Goldblatt hypertension
98. Chronic inhibition of nitric oxide synthesis: A new model of arterial hypertension
99. Sodium and angiotensin in hypertension induced by long-term nitric oxide blockade
100. Angiotensin blockade reverses hypertension during long-term nitric oxide synthase inhibition
101. Role of angiotensin II in hypertension produced by chronic inhibition of nitric oxide synthase in conscious rats
102. Evidence that the autonomic nervous system plays a major role in the L-NAME-induced hypertension in conscious rats
103. Endothelin A receptor blockade alleviates hypertension and renal lesions associated with chronic nitric oxide synthase inhibition
104. Nitric oxide decreases cytokine induced endothelial activation: Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines
105. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants
106. The role of nitric oxide and cell adhesion molecules on the microcirculation in ischaemia-reperfusion
107. Time course of growth factor expression in mercuric chloride acute renal failure
108. Melatonin attenuates the acute renal failure and the oxidative stress induced by mercuric chloride in rats
109. Experimental model of focal sclerosis. I. Relationship to protein excretion in aminonucleoside nephrosis
110. Essential fatty acid deficiency ameliorates acute renal dysfunction in the rat after the administration of aminonucleoside of puromycin
111. Pathogenesis of interstitial fibrosis in chronic purine aminonucleoside nephrosis
112. Inhibition of progression of chronic puromycin aminonucleoside nephrosis by probucol, an antioxidant
113. Essential fatty acid deficiency during acute puromycin nephrosis ameliorates late renal injury
114. Sublethal X-irradiation during the acute puromycin nephrosis prevents the late renal injury: Role of macrophages
115. The role of reactive oxygen species in animal models of glomerular disease
116. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy
117. Mechanism of fibrosis in experimental tracolimus nephrotoxicity
118. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin
119. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake
120. Nephrotoxicity of immunosuppressive drugs
121. Chemokines, chemokine receptors and renal disease: From basic science to pathophysiologic and therapeutic studies
122. Leukocyte adhesion molecules and kidney diseases
123. ICAM-1 directs migration and localization of interstitial leukocytes in experimental glomerulonephritis
124. Cytokine expression, upregulation of intracellular adhesion molecule-1 and leukocyte infiltration in tubulointerstitial nephritis
125. Angiotensin in progressive renal diseases: Theory and practice
126. The role of plasminogen II and plasma plasminogen activator inhibitor-1 in progressive glomerulonephritis
127. Progressive renal disease: The chronic hypoxia hypothesis
128. Is there a mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia
129. Reactive oxygen species: Production and role in the kidney
130. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat
131. Mechanism of angiotensin-induced proteinuria in the rat
132. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension
133. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension
134. Angiotensin-converting enzyme is upregulated in the proximal tubules of rats with intense proteinuria
135. Angiotensin II increases monocyte binding to endothelial cells
136. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin
137. Influence of angiotensin II on circulating adhesion molecules and blood leukocyte count in vivo
138. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis
139. Renal injury from angiotensin II-mediated hypertension
140. The preferential human mononuclear leukocyte chemotactic activity of the substituent tetrapeptides of angiotensin II
141. Activation of human peripheral monocytes by angiotensin II
142. Angiotensin II receptor antagonist reduces graft coronary artery disease and preserves graft status in a murine model
143. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis
144. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism
145. Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure
146. Binding site for angiotensin II in human mononuclear leukocytes
147. Angiotensin regulates cellular immune responses through a calcineurin-dependent pathway
148. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: A possible role for angiotensin II
149. Glomerular macrophages produce reactive oxygen species in experimental glomerulonephritis
150. Mesangiolysis and endothelial lesions due to peroxidative damage in the rabbit
151. Reactive oxygen metabolites cause massive, reversible proteinuria and a glomerular sieving defect without apparent ultrastructural abnormality
152. New mechanism of glomerular injury: Myeloperoxidase-hydrogen peroxide-halide system
153. Morphological correlates of glomerular oxidant injury induced by the myeloperoxidase-hydrogen peroxide-halide system of he neutrophil
154. Oxygen radicals as second messengers for expression of monocyte chemoattractant protein, JE/MCP-1, and the monocyte colony stimulating factor, CSF-1, in response to tumor necrosis factor-α and immunoglobulin G
155. Regulation of RANTES and ICAM expression in mesangial cells
156. A role for oxygen radicals as second messengers
157. The role of chemokines in the initiation and progression of renal disease
158. Oxidatively modified low-density lipoproteins: A potential role in recruitment and retention of monocyte/macrophages during atherogenesis
159. Role of oxidized low-density lipoproreins in atherosclerosis
160. Lisophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocytes in cultured human and rabbit arterial endothelial cells
161. Modified low-density lipoproteins and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells
162. Effects of probucol on renal function in rats with bilateral ureteral obstruction
163. Effect of probucol in the renal function and structure in rats with subtotal kidney ablation
164. Effect of simvastatin of proliferative nephritis and cell-cycle protein expression
165. Effect of pravastatin on type IV collagen secretion and mesangial cell proliferation
166. Atherogenic lipoproteins, oxidative stress and cell death
167. Immunity to bacteria and fungi
168. Heat-shock protein 65 and activated gamma/delta T cells in injured arteries
169. In vivo response of murine gamma delta T cells to heat shock protein-derived peptide
170. Gamma/delta cells
171. Pathogenetic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: Isolation of CD4-T helper cell lines that express gamma delta T-cell antigen receptors
172. The role of gamma-delta T lymphocytes in inflammatory muscle disease
173. Infiltration of the kidney by alpha beta and gamma delta T cells: Effect on progression of IgA nephropathy
174. Antigen-independent activation of resting T cells in the liver of patients with chronic hepatitis
175. Antigen-independent activation of naive and memory resting T cells by a cytokine combination
176. Human naïve T cells activated by cytokine differentiate into split phenotype with functional features intermediate between naïve and memory T cells
177. Activation of dual T cell signaling pathways by the chemokine RANTES
178. IL-7 induces proliferation, variable cytokine-producing ability and IL-2 responsiveness in naïve CD4+ T cells from human cord blood
179. CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex
180. Differential requirements of naïve and memory T cells for CD28 costimulation in autoimmune pathogenesis
181. Antigen-independent, integrin-mediated T cell activation
182. Contribution of mononuclear leukocytes to the progression of experimental focal glomerular sclerosis
183. Mycophenolate mofetil
184. Effect of mycophenolic acid on TNF alpha-induced expression of adhesion molecules in human endothelial cells in vitro
185. Dissociation between anti-proteinuric and anti-hypertensive effects of angiotensin-convetting enzyme inhibition in rats
186. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats
187. Effects of cytokines on nitric oxide pathways in human vasculature
188. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in rabbits
189. Accelerated atherosclerosis in hyperlipidemic C57BL mice treated with cyclosporin A
190. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity
191. Influence of FK506 on the experimental atherosclerosis in cholesterol-fed rabbits
192. Cyclosporin treatment reduces early atherosclerosis in the cholesterol-fed rabbits
193. Glomerular abnormalities in long-term experimental diabetes: Role of hemodynamic and nonhemodynamic factors and effects of antihypertensive therapy
194. Determinants of renal damage in rats with systemic hypertension
195. Pathogenesis of glomerular injury in the fawn-hooded rat: Early glomerular hypertension predicts glomerular sclerosis
196. Renal injury in obese Zucker rats: Glomerular hemodynamic alterations and effects of enalapril
197. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome
198. Mechanisms involved in the progression to glomerular sclerosis induced by systemic hypertension during mild puromycin aminonucleoside nephrosis
199. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass
200. TCV116 prevents the progressive renal injury in rats with extensive renal mass ablation
201. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease (AASK) trial
202. Pyelonephritis: Its relation to vascular lesions and to arterial hypertension
203. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?
204. Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor kappa B activation
205. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation
206. Very low-density lipoprotein stimulates the expression of monocyte chemoatttractant protein-1 in mesangial cells
207. Expression of adhesion molecules in rat renal cortex during experimental hydronephrosis
208. The role of growth factors, cytokines and vasoactive compounds in obstructive nephropathy
209. Differential effects of ACE and ATI receptor inhibition on chemoattractant and adhesion molecule synthesis
210. Fluid shear stress induces a biphasic response of human monocyte chemotactic protein-1 gene expression in vascular endothelium
211. Shear stress increases endothelial platelet-derived growth factor messenger RNA levels
212. Hemodynamics, endothelial gene expression and atherogenesis
213. Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress
214. Fluid shear stress-mediated signal transduction: How do endothelial cells transduce mechanical force into biological responses
215. Evidence for the presence of angiotensins in normal, unstimulated alveolar macrophages and monocytes
216. Granuloma macrophages in murine Schistosomiasis mansoni generate components of the angiotensin system
217. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease
218. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure
219. Mycophenolate mofetil prevents the salt-sensitive hypertension resulting from short-term nitric oxide synthesis inhibition. A role for immune cells and microvascular injury